ttIL-12 pDNA

N/A

Report date: 2024/09/26 15:34:02

Base Information

Drug NamettIL-12 pDNA
Drug Alias NamettIL-12 pDNA
ClassificationCell and gene therapy > Gene therapy > Plasmid
Mechanisms of ActionInterleukin-12 modulators
TargetsInterleukin-12
Therapy Area/IndicationsNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksN/A